Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
57 results about "Cartilage degeneration" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Here's What Happens in Cartilage Degeneration Articular cartilage is the hard but slippery tissue lining the bones within a joint, allowing smooth motion. Cartilage is produced and maintained by chondrocyte cells, and includes fibrous collagen and mesh-like proteoglycans.
Estrogen receptor modulators
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
Owner:MERCK SHARP & DOHME CORP
Selective estrogen receptor modulators
InactiveUS7157604B2Urea derivatives preparationBiocideHormone Receptor ModulatorsPercent Diameter Stenosis
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
Owner:MERCK & CO INC
SUBSTITUTED PHENOXY THIAZOLIDINEDIONES AS ESTROGEN RELATED RECEPTOR-alpha MODULATORS
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
Method for improving cartilage repair and/or preventing cartilage degeneration in a joint
InactiveUS20100215731A1Convenient treatmentRelieve painPowder deliveryBiocideRepair tissueActive agent
The invention is in the field of methods for medical treatment. It provides an improved method for repairing damaged cartilage and / or preventing cartilage degeneration in tissue, in particular in a joint by administering a pharmaceutically active agent directly into the fat pad of a joint. The pharmaceutically active agent is preferably selected from the group consisting of agents that stimulate chondrogenic differentiation and / or cartilage matrix synthesis; agents that inhibit osteogenesis and / or hypertrophy, anti-inflammatory agents, agents that inhibit apoptosis of chondrocytes, agents that inhibit senescence of chondrocytes and agents that enhance lubrication of a joint.
Owner:ACADEMIC HOSPITAL MAASTRICHT +1
Methods of using F-spondin as a biomarker for cartilage degenerative conditions and bone diseases
InactiveUS20100015129A1Reduce expressionDecreases activity/functionOrganic active ingredientsMicrobiological testing/measurementBone formationArthritis
Methods for identifying subjects having, or at risk for developing, osteoarthritis or other cartilage degenerative conditions by measuring levels of expression of F-spondin are provided. Assays, kits and methods for determining and assaying the presence of F-spondin in individual patients are disclosed. Oligonucleotide probes and primers for use in the assays, kits and methods are described. Assays and methods are disclosed for identifying candidate compounds that modulate F-spondin levels of expression and / or function or for determining and evaluating an individual's response to drugs and therapeutic agents, are provided. The invention further relates to the modulation of F-spondin, particularly the inhibition of F-spondin, for increasing or stimulating bone formation and / or growth and mediating the alleviation of bone disease, disorders or conditions. The use of F-spondin, an active fragment thereof, or a modulator thereof for enhancing cartilage repair or preventing or treating cartilage degeneration, degenerative diseases or arthritic conditions is also provided.
Owner:NEW YORK UNIV SCHOOL OF MEDICINE
Substituted phenoxy n-alkylated thiazolidinediones as estrogen related receptor-alpha modulators
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
Arthroscopic impedance probe to detect cartilage degeneration
InactiveUS6856834B2Modulus is reducedHigh inflation pressureStrain gaugePerson identificationCell-Extracellular MatrixECM Protein
The change in tissue impedance due to the change in the extracellular matrix that results from the degradation of cartilage is utilized to detect degradation of articular cartilage. A probe comprising electrodes is applies a current to the articular cartilage which results in a current distribution and electric field within the cartilage, along with an associated voltage drop across the electrodes. The amplitude of this voltage drop is then measured and divided by the current applied to determine the tissue impedance. By measuring the impedance of patient tissue and comparing the detected patient impedance to a normal value for the tissue from clinically normal tissue, a determination of whether the patient tissue is degraded and the extent of degradation is possible. Preferably, the impedance is measured using a probe with interdigitated electrodes. By changing which electrodes are utilized, the wavelength of the current distribution changes, allowing the probe to image depth dependent focal lesions.
Owner:MASSACHUSETTS INST OF TECH
Estrogen receptor modulators
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
Owner:MERCK & CO INC
Estrogen receptor modulators
The present invention relates to compounds and derivatives thereof, their synthesis, and their use as estrogen receptor modulators. The compounds of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid disease, hot flashes, increased levels of LDL cholesterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restinosis, gynacomastia, vascular smooth muscle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
Owner:MERCK SHARP & DOHME LLC
Cartilage targeting double-drug-loaded nano-microspheres with optical thermal response characteristic and preparation method and application thereof
ActiveCN112023060AReduce degenerationImprove abilitiesPowder deliveryOrganic active ingredientsMicrosphereMetal-organic framework
The invention relates to a preparation method and application of cartilage targeting double-drug-loaded nano-microspheres with the optical thermal response characteristic. According to thecartilage targeting double-drug-loaded nano-microspheres with the optical thermal response characteristic, small-particle-size mesoporous polydopamine is used as a matrix, the matrix is sequentially subjected toa cyclic reaction with FeCl3. 6H2O and H3BTC, and the surface of the mesoporous polydopamine is modified to form a metal organic framework. After the synthesized MPDA-MOF (referred to as MPM hereinafter) nano-microspheres react with EDC and NHS solution, carboxyl groups on the surface of MOF are activated, and by connection with amino groups in type II collagen targeting peptide (WYRGRL), composite nano-microspheres (MPMW) of which surfaces are loaded with a cartilage targeting peptide are formed. Double factors of bilirubin (Br) and rapamycin (Rap) are correspondingly loaded in pore passagesof an MOF shell layer and the mesoporous polydopamine, and finally, the RB@MPMW is obtained. The nano-microspheres have the advantages of high optical thermal response characteristic, good biocompatibility, active cartilage targeting, delay on in-vivo cartilage degeneration and the like, and can be used for the targeted therapy of osteoarthritis cartilage degeneration.
Owner:SHANGHAI FIRST PEOPLES HOSPITAL
Estrogen receptor modulators
The present invention relates to compounds and derivatives thereof, their cynthesis, and their use as estrogen receptor modulators. The compound of the instant invention are ligands for estrogen receptors and as such may be useful for treatment or prevention of a variety of conditions related to estrogen functioning including: bone loss, bone fractures, osteoporosis, cartilage degeneration, endometriosis, uterine fibroid desease, hot flashes, increased levels of LDL cholestterol, cardiovascular disease, impairment of cognitive functioning, cerebral degenerative disorders, restenosis, gynecomastia, vascular smooth muschle cell proliferation, obesity, incontinence, and cancer, in particular of the breast, uterus and prostate.
Owner:MERCK SHARP & DOHME CORP
Methods of using bone morphogenic proteins as biomarkers for determining cartilage degeneration and aging
InactiveUS20070015178A1Microbiological testing/measurementDisease diagnosisDiseaseOsteogenic proteins
Methods are provided for determining cartilage degeneration, regeneration, or aging in a joint tissue in a patient by measuring levels of osteogenic protein-1 (OP-1) protein and / or mRNA in synovial fluid or joint tissue. The methods according to the invention are useful for detecting, diagnosing, predicting, determining a predisposition for, or monitoring joint tissue degeneration, regeneration, or aging in a patient including inflammatory joint disease or age-related disorders.
Owner:RUSH PRESBYTERIAL ST LUKES MEDICAL CENT +1
Arthroscopic impedance probe to detect cartilage degeneration
The change in tissue impedance due to the change in the extracellular matrix that results from the degradation of cartilage is utilized to detect degradation of articular cartilage. A probe includes electrodes that apply a current to the articular cartilage which results in a current distribution and electric field within the cartilage, along with an associated voltage drop across the electrodes. The amplitude of this voltage drop is then measured and divided by the current applied to determine the tissue impedance. By measuring the impedance of patient tissue and comparing the detected patient impedance to a normal value for the tissue from clinically normal tissue, a determination of whether the patient tissue is degraded, and a determination of the extent of degradation is possible. Preferably, the impedance is measured using a probe with interdigitated electrodes. By changing which electrodes are utilized, the wavelength of the current distribution changes, allowing the probe to image depth dependent focal lesions.
Owner:MASSACHUSETTS INST OF TECH
Pharmaceutical agent having long-lasting effect of treating arthritic disorders
The present invention relates to an injection solution for intra-articular administration for treating arthritic disorders comprising a cross-linked hyaluronic acid derivative wherein part of functional groups of a hyaluronic acid are cross-linked with a cross-linking group to the extent of 0.6 to 15% of cross-linking extent as an active ingredient in an amount having a long-lasting analgesic effect and a pharmaceutically acceptable carrier, and an analgesic composition for suppressing a cartilage degeneration caused by arthritic disorders or a composition for suppressing a cartilage degeneration or an inflammation of synovium caused by arthritic disorders each comprising the cross-linked hyaluronic acid derivative and a pharmaceutically acceptable carrier.
Owner:SEIKAGAKU KOGYO CO LTD
Markers of matrix gene expression and cellular differentiation in chondrocytes
InactiveUS20100330036A1Improve stabilityPrevent and delay dedifferentiationBiocideMicrobiological testing/measurementConnective tissueCartilage degeneration
The invention relates generally to the field of tissue engineering. More particularly, the present invention relates to methods for identifying a population of cells suitable for the repair of connective tissue, including cartilage. The invention further provides methods and compositions related to the generation of a population of cells suitable for the repair of cartilage, in particular in the repair of cartilage degeneration associated with osteoarthritis. Methods of using said cells thus identified or thus generated, in methods to extend the period of cell manipulation, i.e. to increase the yield of cells suitable in the aforementioned methods, are also provided by the present invention.
Owner:UNIV GENT
Pharmaceutical composition including an HIF-2 alpha inhibitor as an active ingredient for preventing or treating arthritis
The present invention relates to a pharmaceutical composition for preventing or treating arthritis, including, as an active ingredient, a material which inhibits the expression of the hypoxia-inducible factor-2α (HIF-2α) gene or the activity of the HIF-2α protein. According to the present invention, the HIF-2α of the present invention increases the expression thereof in chondrocytes or tissue in which osteoarthritis is induced, and triggers the expression of various cartilage degeneration factors and the activation of mitogen-activated protein (MAP) kinase. In addition, when HIF-2α is inhibited, the expression level of cartilage degeneration factors and the phosphorylation of MAP kinase are significantly reduced by the inhibited degree of HIF-2α. Thus, the composition of the present invention may be applied to the prevention or treatment of arthritis, and may be used for the development of therapeutics for arthritis.
Owner:GWANGJU INST OF SCI & TECH
Antigen-binding polypeptides against cartilage degeneration
InactiveUS20110002927A1Long contactDegeneration can be decreased and inhibitedAnimal cellsSugar derivativesMedicineAntigen binding
Owner:DELENEX THERAPEUTICS
Method for improving cartilage repair and/or preventing cartilage degeneration in a joint
InactiveUS20130123314A1Convenient treatmentRelieve painBiocidePeptide/protein ingredientsEccentric hypertrophyActive agent
The invention is in the field of methods for medical treatment. It provides an improved method for repairing damaged cartilage and / or preventing cartilage degeneration in tissue, in particular in a joint by administering a pharmaceutically active agent directly into the fat pad of a joint. The pharmaceutically active agent is preferably selected from the group consisting of agents that stimulate chondrogenic differentiation and / or cartilage matrix synthesis; agents that inhibit osteogenesis and / or hypertrophy, anti-inflammatory agents, agents that inhibit apoptosis of chondrocytes, agents that inhibit senescence of chondrocytes and agents that enhance lubrication of a joint.
Owner:MAASTRICHT UNIVERSITY +1
Magnesium hyaluronate for treating osteoarthritis and preparation method and application thereof
InactiveCN107840897AEffective treatmentOrganic active ingredientsPeptide/protein ingredientsMagnesium saltMedicine
The invention discloses magnesium hyaluronate for treating osteoarthritis and a preparation method and application thereof. The preparation method of the magnesium hyaluronate comprises adding a magnesium salt aqueous solution into an appropriate amount of a sodium hyaluronate aqueous solution for precipitation so that an associated complex of hyaluronic acid and magnesium ions is obtained. A testresult shows that compared with the sodium hyaluronate, the drug magnesium hyaluronate can well delay cartilage degeneration, so as to achieve better treatment on osteoarthritis.
Owner:XIANGYA HOSPITAL CENT SOUTH UNIV
Substituted phenoxy thiazolidinediones as estrogen related receptor-α modulators
Owner:JANSSEN PHARMA NV
Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-α modulators
The present invention relates to compounds of Formula (I),methods for preparing these compounds, compositions, intermediates and derivatives thereof and for treating a condition including but not limited to ankylosing spondylitis, artherosclerosis, arthritis (such as rheumatoid arthritis, infectious arthritis, childhood arthritis, psoriatic arthritis, reactive arthritis), bone-related diseases (including those related to bone formation), breast cancer (including those unresponsive to anti-estrogen therapy), cardiovascular disorders, cartilage-related disease (such as cartilage injury / loss, cartilage degeneration, and those related to cartilage formation), chondrodysplasia, chondrosarcoma, chronic back injury, chronic bronchitis, chronic inflammatory airway disease, chronic obstructive pulmonary disease, diabetes, disorders of energy homeostasis, gout, pseudogout, lipid disorders, metabolic syndrome, multiple myeloma, obesity, osteoarthritis, osteogenesis imperfecta, osteolytic bone metastasis, osteomalacia, osteoporosis, Paget's disease, periodontal disease, polymyalgia rheumatica, Reiter's syndrome, repetitive stress injury, hyperglycemia, elevated blood glucose level, and insulin resistance.
Owner:JANSSEN PHARMA NV
Mirna biomarkers for cartilage degeneration
There is disclosed herein methods, uses and systems for the detection, diagnosis, prognosis, treatment or prevention of a disease or condition comprising cartilage degeneration in a subject that is in need thereof. The methods comprise the use, inhibition or measurement of at least one of miR-181 a-5p and miR-4454, in the subject.
Owner:UNIV HEALTH NETWORK
Pharmaceutical composition including an hif-2 alpha inhibitor as an active ingredient for preventing or treating arthritis
The present invention relates to a pharmaceutical composition for preventing or treating arthritis, including, as an active ingredient, a material which inhibits the expression of the hypoxia-inducible factor-2α (HIF-2α) gene or the activity of the HIF-2α protein. According to the present invention, the HIF-2α of the present invention increases the expression thereof in chondrocytes or tissue in which osteoarthritis is induced, and triggers the expression of various cartilage degeneration factors and the activation of mitogen-activated protein (MAP) kinase. In addition, when HIF-2α is inhibited, the expression level of cartilage degeneration factors and the phosphorylation of MAP kinase are significantly reduced by the inhibited degree of HIF-2α. Thus, the composition of the present invention may be applied to the prevention or treatment of arthritis, and may be used for the development of therapeutics for arthritis.
Owner:GWANGJU INST OF SCI & TECH
Pharmaceutical compositions for treating/preventing motor organ diseases
InactiveUS20090104280A1Reduced activityDecrease of life-spanBiocidePowder deliveryDiseaseRabbit model
Fullerene inhibited the decrease in cell proliferation ability of chondrocytes which is observed when cultured chondrocytes are treated with a cartilage degenerating factor (IL-1β or H2O2). Fullerene inhibited production of cartilage matrix-degrading enzymes (matrix metalloprotease (MMP)-1, 3 and 13) which is induced in cultured chondrocytes by cartilage degenerating factors. Fullerene restored the decrease in cartilage matrix (proteoglycan) synthesizing ability which is observed in treating cultured chondrocytes with cartilage degenerating factors. In an analysis using an osteoarthritis rabbit model, the progress of cartilage degeneration was reduced by administering fullerene. Moreover, the dynamic friction coefficient was decreased by adding fullerene to synovial fluid.
Owner:MITSUBISHI CORPORATION +1
Composition containing alpinia oxyphylla extract as active ingredient for prevention, alleviation, or treatment of osteoarthritis
InactiveCN111093398AReduce expressionGood for restoring cartilage damageDispersion deliverySkeletal disorderWhite blood cellCartilage lesion
Owner:KOREA INST OF ORIENTAL MEDICINE
Cationic contrast agents and methods of using the same
Gadolinium complexes for use as contrast agents, and methods for making and using the gadolinium complexes, are described. The contrast agent complexes preferably have a net positive charge, and can electrostatically interact with glycosaminoglycans to improve the delineation of fine tears within cartilage, detection of cartilage degeneration, or assessment of cartilage thickness, morphology, or glycosaminoglycan content via magnetic resonance imaging.
Owner:THE TRUSTEES OF THE UNIV OF PENNSYLVANIA
Application of 11beta-HSD2 and epigenetics as early markers of articular cartilage dysplasia and osteoarthritis susceptibility
The invention discloses the application of 11beta-HSD2 and epigenetics as early markers of articular cartilage dysplasia and osteoarthritis susceptibility. Research results show that in comparison with a normal control group, the level of histone acetylation and expression of the 11beta-HSD2 promoter region in the IUGR neonatal umbilical cord mesenchymal stem cells or the whole umbilical cord is decreased; and cartilage differentiation ability of the IUGR neonatal umbilical cord mesenchymal stem cells is lower, and cartilage degeneration similar to osteoarthritis is more likely to occur underthe action of glucocorticoids. Therefore, by detecting the expression and epigenetic levels of umbilical cord 11beta-HSD2 gene, the risk of cartilage dysplasia and osteoarthritis in adulthood is judged. The invention provides the research basis for the early warning technology of articular cartilage dysplasia and fetal osteoarthritis in adulthood, and also provides new ideas for comprehensive prevention and treatment of fetal osteoarthritis in adulthood.
Owner:WUHAN UNIV
Medicine for treating osteoarthritis
InactiveCN101357124ADelay the degradation processRepair lesionOrganic active ingredientsAntipyreticSide effectMass ratio
The invention discloses a medicine which cures osteoarthritis and is a compound which is formed by combining (S)-ibuprofen and dextrosamine or the medicine salt thereof according to 1:3 of mass ratio. The (S)-ibuprofen and the dextrosamine are prepared into compound preparation. The characteristics of rapid drug effects and strong abirritation of the (S)-ibuprofen can be used for rapidly relieving symptoms on the one hand; on the other hand, the dextrosamine can defer cartilage degeneration process, repairs cartilage pathological changes, and prevents, even reverses the disease process. Meanwhile, the (S)-ibuprofen and the dextrosamine are prepared into the compound preparation, which can reduce the dose of single medicine and further reduce the toxic side effects. The compound preparation prepared by the (S)-ibuprofen and the dextrosamine of the invention becomes a new medicine which can cure the osteoarthritis.
Owner:NAT INST OF PHARMA R & D CO LTD
Pharmaceutical compositions for treating/preventing motor organ diseases
Owner:MITSUBISHI CORPORATION +1
JAK kinase inhibitor and application thereof
The invention discloses a JAK kinase inhibitor and an application thereof. The JAK kinase inhibitor is a compound represented by a formula I or a stereoisomer, a tautomer or pharmaceutically acceptable salt or a solvate or a prodrug of the compound; the invention further provides the application of the compound represented by the formula I in preparation of drugs for preventing or treating JAK kinase related diseases, and in particular, relates to the application in preparing medicines for preventing and / or treating diseases related to cartilage degeneration and bone and / or joint degeneration,diseases related to inflammation or immune response, endotoxin-driven disease states, cancers and organ transplantation rejection.
Owner:JIANGSU CAREFREE PHARM CO LTD
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com